Sign in or create an account to add this stock to your watchlist.
About R1 RCM (NASDAQ:RCM)
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves single or multi-hospital healthcare systems, and their respective affiliated ambulatory clinics and physician practice groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Industry, Sector and Symbol
Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
SymbolNASDAQ:RCM
CUSIP00438V10
Phone312-324-7820
Debt
Debt-to-Equity RatioN/A
Current Ratio2.23
Quick Ratio2.23
Price-To-Earnings
Trailing P/E Ratio-18.05
Forward P/E Ratio-52.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$449.80 million
Price / Sales1.94
Cash FlowN/A
Price / CashN/A
Book Value$0.23 per share
Price / Book34.52
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$-58,800,000.00
Net Margins-14.47%
Return on Equity-45.77%
Return on Assets-7.12%
Miscellaneous
Employees9,965
Outstanding Shares109,660,000
R1 RCM (NASDAQ:RCM) Frequently Asked Questions
What is R1 RCM's stock symbol?
R1 RCM trades on the NASDAQ under the ticker symbol "RCM."
How were R1 RCM's earnings last quarter?
R1 RCM (NASDAQ:RCM) announced its quarterly earnings results on Wednesday, May, 9th. The financial services provider reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.11. The financial services provider earned $147.30 million during the quarter, compared to analyst estimates of $146 million. R1 RCM had a negative net margin of 14.47% and a negative return on equity of 45.77%. View R1 RCM's Earnings History.
When is R1 RCM's next earnings date?
What price target have analysts set for RCM?
3 brokerages have issued 1 year price objectives for R1 RCM's shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate R1 RCM's share price to reach $9.3333 in the next twelve months. View Analyst Ratings for R1 RCM.
What are Wall Street analysts saying about R1 RCM stock?
Here are some recent quotes from research analysts about R1 RCM stock:
- 1. According to Zacks Investment Research, "R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. " (5/1/2018)
- 2. Cantor Fitzgerald analysts commented, "The revenue cycle management market represents a significant opportunity. Revenue cycle management remains an underdeveloped and fragmented market. There are many different solutions available, including consulting arrangements, point-solution technologies, and transactional outsourcing. Many providers use fragmented solutions. As a result, healthcare organizations are increasingly dissatisfied with currently available options and see a strong commercial partner to help improve performance and increase ROI. We estimate the market opportunity will increase to almost $70 billion by 2020. In addition, increasing consolidation among providers should lead to additional outsourcing. We expect revenue cycle outsourcing to grow to $7.7 billion by 2020 from $3.8 billion in 2015. We estimate the ambulatory market opportunity is approximately $30-40 billion. As hospital systems acquire physician offices, we expect the ambulatory market opportunity to expand." (3/13/2018)
Who are some of R1 RCM's key competitors?
Who are R1 RCM's key executives?
R1 RCM's management team includes the folowing people:
- Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 47)
- Mr. Christopher Simon Ricaurte, CFO & Treasurer (Age 58)
- Mr. Thomas A. Lesica, Exec. VP of Bus. Transformation (Age 58)
- Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 48)
- Mr. Richard B. Evans Jr., Principal Accounting Officer, Sr. VP and Corp. Controller (Age 50)
Has R1 RCM been receiving favorable news coverage?
Headlines about RCM stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. R1 RCM earned a media sentiment score of 0.22 on Accern's scale. They also gave news articles about the financial services provider an impact score of 47.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are R1 RCM's major shareholders?
R1 RCM's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include TCP-ASC ACHI SERIES LLLP (59.80%), BlackRock Inc. (5.03%), JASPER RIDGE PARTNERS, L.P. (3.00%), Eversept Partners LLC (1.74%), Dimensional Fund Advisors LP (0.76%) and Balter Liquid Alternatives LLC (0.59%). Company insiders that own R1 RCM stock include Alex Mandl, John B Henneman III and Joseph Gerard Flanagan. View Institutional Ownership Trends for R1 RCM.
Which institutional investors are selling R1 RCM stock?
RCM stock was sold by a variety of institutional investors in the last quarter, including SLS Management LLC, Wells Fargo & Company MN, Unterberg Capital LLC, California Public Employees Retirement System and MetLife Investment Advisors LLC. View Insider Buying and Selling for R1 RCM.
Which institutional investors are buying R1 RCM stock?
RCM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., 22NW LP, Dimensional Fund Advisors LP, Eversept Partners LLC, Millennium Management LLC, JPMorgan Chase & Co., Balter Liquid Alternatives LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought R1 RCM stock in the last two years include Alex Mandl, John B Henneman III and Joseph Gerard Flanagan. View Insider Buying and Selling for R1 RCM.
How do I buy shares of R1 RCM?
Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is R1 RCM's stock price today?
One share of RCM stock can currently be purchased for approximately $7.94.
How big of a company is R1 RCM?
R1 RCM has a market capitalization of $898.09 million and generates $449.80 million in revenue each year. The financial services provider earns $-58,800,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. R1 RCM employs 9,965 workers across the globe.
How can I contact R1 RCM?
R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The financial services provider can be reached via phone at 312-324-7820 or via email at [email protected]
MarketBeat Community Rating for R1 RCM (RCM)
MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote "Outperform" if you believe RCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
R1 RCM (NASDAQ:RCM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for R1 RCM in the last 12 months. Their average twelve-month price target is $9.3333, suggesting that the stock has a possible upside of 17.55%. The high price target for RCM is $10.00 and the low price target for RCM is $9.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.67 | 2.67 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.3333 | $9.3333 | $5.00 | $5.00 |
| Price Target Upside: | 17.55% upside | 31.46% upside | 44.72% upside | 44.72% upside |
R1 RCM (NASDAQ:RCM) Consensus Price Target History
R1 RCM (NASDAQ:RCM) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
R1 RCM (NASDAQ:RCM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
R1 RCM (NASDAQ RCM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 59.40%
Institutional Ownership Percentage: 47.24%
R1 RCM (NASDAQ RCM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/16/2016 | John B Henneman III | Director | Buy | 50,000 | $1.80 | $90,000.00 | 100 |  |
| 8/11/2016 | Alex Mandl | Director | Buy | 200,000 | $1.59 | $318,000.00 | 65,700 | |
| 8/10/2016 | Joseph Gerard Flanagan | CEO | Buy | 100,000 | $1.56 | $156,000.00 | 1,431,814 | |
(Data available from 1/1/2013 forward)
R1 RCM (NASDAQ RCM) News Headlines
| Source: |
|
R1 RCM (NASDAQ:RCM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
R1 RCM (NASDAQ:RCM) Income Statement, Balance Sheet and Cash Flow Statement
R1 RCM (NASDAQ RCM) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
